Neurogene opened lower at $24.77, compared with its previous close of $25.10. In the last trading session, the stock traded between $22.70 and $24.99. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Neurogene is now worth
$ 158.64
Giving a profit of
$ 58.64 (58.64%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.15 (-4.57%)
Day High
$24.99
Day Low
$22.70
Day Open
$24.77
Prev Close
$25.10
Volume
1,96,482
1W Return
-13.32%
1M Return
-2.00%
3M Return
-32.91%
6M Return
-22.45%
1Y Return
-22.40%
Fundamentals
Market Cap ($ Mn)
496
PE Ratio
-
PB Ratio
2.66
PEG Ratio
-
ROE
-32.13%
ROCE
-35.16%
EPS (TTM)
-
Investment Returns
1 Week
-13.32%
1 Month
-2.00%
3 Months
-32.91%
6 Months
-22.45%
9 Months
41.82%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
Neurogene Q3 Results: Loss narrows to $1.05 per share vs estimate
Neurogene posted a loss of $1.05 per share in Q3. The figure beat the analyst consensus estimate of $(1.36). Losses widened 6.06% YoY compared to $0.99 last year.
3 days ago
20Oct
Neurogene to present NGN-401 Rett syndrome data at ESGCT congress
Neurogene Inc. will present NGN-401 data at the ESGCT 33rd Annual Congress in Hamburg, Germany, from October 27-30, 2026. Presentations will highlight rapid transgene expression and miRNA-based regulation of *MECP2* using EXACT™ technology. The company will discuss intracerebroventricular (ICV) administration as a standard delivery strategy for CNS gene therapies. NGN-401 is in late-stage development and holds Breakthrough Therapy and RMAT designations from the FDA.
23 days ago
7Oct
Jennison Associates reports 11.1% stake in Neurogene as of Sept 30
Jennison Associates holds 11.1% of Neurogene Inc. Stake reported as of September 30 in SEC filing. Disclosure made via Schedule 13G form.
1mo ago
6Oct
Neurogene grants stock options to five new employees under Nasdaq rules
Neurogene granted options for 8,340 shares to five new employees. Awards approved under Nasdaq Listing Rule 5635(c)(4). Options vest over four years with 25% cliff at first anniversary. Exercise price equals closing stock price on October 5, 2026.
1mo ago
5Sep
Neurogene grants 38,330 stock options to two new employees
Neurogene granted 38,330 stock options to two new employees. Awards issued under Nasdaq Rule 5635(c)(4) as an inducement. Exercise price set at closing price on September 1, 2026. Options vest over four years with 25% cliff after one year.
2mo ago
11Aug
Neurogene Q2 Results: EPS widens to $(1.53), misses estimates
Neurogene missed Q2 EPS estimates with a loss of $(1.53) per share, down from $(1.05) YoY. The 10.07% miss against the $(1.39) consensus signals deeper operational challenges than expected.
